1. India Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Glenmark Pharmaceuticals Limited

Glenmark Pharmaceuticals Limited

GLENMARK.NS
Glenmark Pharmaceuticals LimitedIN flagNational Stock Exchange of India
2,270.90
INR
+59.90
- -
640.85BMarket Cap
Glenmark Pharmaceuticals Limited
GLENMARK.NS
(National Stock Exchange of India)

Recent

price

2,270.90

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
FRC
109.21
148.7
183.57
218.56
240.42
262.53
314.13
316.96
343.95
368.48
382.96
431.45
405.15
412.36
465.9
592.2
592.12
Revenue per Share
16.95
17.03
22.91
20.01
17.52
25.01
32.46
27.44
32.78
27.5
34.38
33.37
10.53
-53.22
37.11
48.26
48.25
Basic EPS, GAAP
19.61
19.19
23.94
31.5
17.76
12.28
23.3
58.41
46.93
16.34
12.63
11.29
0.62
-41.25
-55.94
73.97
- -
Free Cash Flow per Basic Share
0.47
0.47
2.37
2.33
2.34
2.42
2.4
2.41
2.41
2.43
2.5
3.29
4.84
4.17
2.5
5
- -
Dividend per Share
50.62
66.24
84.75
100.61
114.27
134.13
163.38
188.55
199.99
225.32
257.36
327.43
336.16
279.93
312.83
1
1
Book Value per Share
38.18
45.88
55.91
61.38
63.73
98.57
127.78
144.54
137.07
137.79
167.61
253.49
263.07
230.82
261.86
283.69
283.65
Tangible Book Value per Share
270
270
271
271
271
281
282
282
282
282
282
282
282
282
282
282
282
Basic Weighted Avg Shares
29,491
40,206
49,691
59,236
65,216
73,700
88,638
89,436
97,051
103,972
108,060
121,742
114,319
116,355
131,458
167,114
167,114
Sales/Revenue/Turnover
21.64
15.33
18.54
14.92
11.69
15.79
16.47
14.13
12.98
12.33
15.88
15.11
9.44
5.42
14.19
23.93
23.93
Operating Margin (%)
947
978
1,270
2,168
2,600
2,691
5,765
3,541
3,259
4,172
4,436
4,867
6,113
6,308
4,860
5,735
5,735
Depreciation Expense
4,578
4,603
6,200
5,423
4,753
7,021
9,160
7,742
9,250
7,760
9,700
9,417
2,972
-15,017
10,471
13,619
13,619
Net Income, GAAP
4.92
4.87
14.98
21.71
20.03
30.14
27.32
27.42
28.88
29.2
29.83
31.06
137.34
5,116.71
25.16
31.38
31.38
Effective Tax Rate (%)
15.52
11.45
12.48
9.15
7.29
9.53
10.33
8.66
9.53
7.46
8.98
7.74
2.6
-12.91
7.97
8.15
8.15
Profit Margin (%)
3,397
10,454
15,254
18,135
16,120
19,044
41,708
37,008
26,757
26,776
31,586
35,929
56,205
16,095
33,284
49,233
49,233
Working Capital
6,171
13,125
19,203
24,287
25,744
24,873
45,363
41,418
35,738
42,743
41,129
27,717
40,293
1,517
6,989
4,863
4,863
LT Debt
20,639
24,266
27,874
29,966
30,001
42,699
49,390
55,887
56,048
60,701
70,643
94,381
98,393
78,475
88,491
105,118
105,118
Total Equity
14.42
13.26
15.27
11.6
9.26
10.77
11.87
9.26
8.87
8.55
10.38
10.01
-2.9
-267.81
13.65
24.48
24.48
Return on Invested Capital (%)
22.73
15.76
16.36
12.38
9.72
11.29
12.74
10.17
11.6
9.64
10.24
8.49
0.62
-232.79
11.77
25.25
25.25
Return on Capital (%)
65.69
29.15
30.36
21.6
16.32
20.45
21.87
15.59
16.87
12.93
14.24
11.41
3.17
-17.28
12.52
30.76
30.76
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
ST Debt
4,466
- -
1,072
LT Borrowings
5,328
- -
- -
LT Finance Leases
2,448
- -
4,863
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
282
- -
282
Market Capitalization
555,234
578,670
601,631

Working Capital

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
Total Current Assets
114,532
- -
112,997
Cash, Cash Equivalents & STI
29,583
- -
14,010
Accounts Receivable, Net
37,731
- -
49,634
Inventories
32,807
- -
34,308
Total Current Liabilities
69,595
- -
63,764
Payables & Accruals
- -
- -
- -
ST Debt
4,466
- -
1,072
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
10.29%
9.83%
18.79%
Free Cash Flow
-686.97%
-1,400.7%
-232.25%
Net Income, GAAP
-77.29%
-163.25%
30.06%
Sales/Revenue/Turnover
8.92%
9.69%
27.12%
Total Cash Common Dividend
- -
25.04%
100.21%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
29,985
31,607
24,603
30,160
116,355
2025
32,233
34,005
33,019
32,201
131,458
2026
30,593
60,038
38,880
37,603
167,114

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
5.31
-2.9
-12.45
- -
-53.22
2025
12.06
12.55
12.33
0.16
37.11
2026
1.66
21.63
14.29
10.68
48.26

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
4.17
2025
- -
- -
- -
- -
2.5
2026
- -
- -
- -
- -
5
Similar Companies
The BC Bud Corporation (BCBCF)
OptiNose, Inc. (OPTN)
Neoleukin Therapeutics, Inc. (NLTX)
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (600196.SS)
Blau Farmacêutica S.A. (BLAU3.SA)
Krebs Biochemicals & Industries Limited (KREBSBIO.NS)
Business
Glenmark Pharmaceuticals Limited (GLENMARK.NS) is an India-based research-led global pharmaceutical company that discovers, develops, manufactures, and markets a broad range of branded and generic formulations across multiple therapeutic areas, including dermatology, respiratory, gastroenterology, oncology, cardiovascular, and anti-infectives. The company offers innovative branded generics and specialty products such as salt forms and novel delivery systems; key brands include Telma (telmisartan for hypertension), Candid (clotrimazole for dermatology), and Foracort (budesonide/formoterol for respiratory conditions); it also provides active pharmaceutical ingredients (APIs), contract research and manufacturing services (CRAMS), and over-the-counter (OTC) products. Glenmark operates in more than 80 countries worldwide, with key markets in India, the United States, Europe (including Germany, Italy, and the UK), Latin America, Africa, and Asia-Pacific, serving physicians, hospitals, pharmacies, and institutional customers through a network of subsidiaries and joint ventures [web:previous]. Founded in 1977 and headquartered in Mumbai, India, Glenmark Pharmaceuticals maintains manufacturing facilities in India, the Czech Republic, and Argentina, and focuses on high-growth segments like respiratory and dermatology therapies while expanding its U.S. generics portfolio and novel drug delivery platforms. In recent developments, the company launched GMRx2, a first-in-class angiotensin receptor-neuropeptide Y (NPY) antagonist for uncontrolled hypertension, completing Phase 2b trials in 2024 with positive topline results showing superior blood pressure reduction; it also secured $100 million upfront from AbbVie in a 2023 licensing deal for GRC 54276, an oral obesity treatment, potentially worth up to $1 billion in milestones [web:previous]. Additionally, Glenmark resolved U.S. FDA import alerts for its Pithampur facilities in 2024, enabling resumed exports; formed a strategic R&D collaboration withFrontier Medicines in 2024 for cancer therapies targeting undruggable proteins; and divested non-core Argentina operations to Biopas in 2023 while acquiring a majority stake in India's Siddhant Chemins in 2024 to bolster API capabilities [web:previous].

Company News

APIChatGPT

  • feeds.newsfilecorp.com

    Cosmo Welcomes the Launch of Winlevi(R) in Key European Markets by Its Partner Glenmark

  • prnewswire.com

    Cosmo y Glenmark anuncian la autorización de comercialización de Winlevi®